Kyverna Therapeutics, Inc.
KYTXKyverna Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing cell therapies for patients with autoimmune diseases.
Earnings
Next report
Aug 11, 2026 (in a month)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
Profile
Kyverna Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing cell therapies for patients with autoimmune diseases. The company's core value proposition centers on its lead product candidate, miv-cel, a differentiated anti-CD19 autologous CAR T-cell therapy designed to deeply deplete B cells and achieve durable, treatment-free remission. By leveraging a human CAR construct licensed from the NIH, the company aims to provide a curative paradigm shift over current standard-of-care chronic treatments.
Kyverna is a pioneer in applying CAR T-cell therapy to autoimmune diseases, holding a first-mover advantage with a completed registrational trial in Stiff Person Syndrome.
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s market cap?
- Kyverna Therapeutics, Inc. (KYTX) has a market capitalization of $596.4M and trades on NASDAQ.
- Who are Kyverna Therapeutics, Inc.'s competitors?
- Kyverna Therapeutics, Inc.'s key competitors include Cabaletta Bio, Inc., Cartesian Therapeutics, Inc., Novartis AG, and others. These companies compete in similar markets and product categories.
- Who does Kyverna Therapeutics, Inc. partner with?
- Kyverna Therapeutics, Inc.'s notable partners include National Institutes of Health, Intellia Therapeutics, Inc., ElevateBio BaseCamp, Inc., and others.
- Where is Kyverna Therapeutics, Inc. headquartered?
- Kyverna Therapeutics, Inc. is headquartered in United States of America and employs approximately 100 people. It has been publicly traded since 2024.